Menocal TG, Velázquez MER

Language: Spanish
References: 12
Page: 13-16
PDF size: 86.36 Kb.

ABSTRACT

Objective: To evaluate clinical effectiveness of a new technique for application of the hormonal therapy with microspheres on suspension drugs. Patients and methods: In a prospective and comparative study carried out in Angeles Hospital of Querétaro, were supplemented 30 patients with progesterone made with microspheres on suspension, who voluntary accepted with previously signed informed consent. The dose of 200 mg of Prosphere® was repeated every week until the gestation reached 12 weeks. There were two groups: A (n = 15) with common technique of application and B (n = 15) with the new technique. Follow up visits included clinical examinations every week, to try to find symptoms or local vs systemic reactions. Results: Demography and nutritional characteristics were similar on both groups and vitality of pregnancies until the 12 weeks, was observed at 100%. With the common technique (group A) 87% had persistent local pain and 20% a local lesion. The pain with the new technique (group B) was transitory and there not been any local reactions. Conclusions: The new propose technique, were better than the common technique around the clinical effectiveness, and may be it can improve the attachment to the hormonal treatment with the new microspheres on suspension drugs.

REFERENCES

1. The North American Menopause Society NAMS. Estrogen and progestogen use in postmenopausal women. Menopause 2008; 4: 584-603.

2. Menocal TG, Sánchez UR, Dueñas RJ y cols. Progesterona en microesferas para el tratamiento en infertilidad. Acta Médica Grupo Ángeles 2008; 1: 8-13.

3. Campero R. Estudio farmacocinética, multidosis de tres formulaciones de suspensión inyectable de progesterona. Clin Asoc Invest 2005: 06-08.

4. Unidad de Investigación Fármaco Clínica de la Asociación Mexicana para la Investigación Clínica, AMIC. Estudio de biodisponibilidad de microesferas en suspensión. Conferencia Salud Femenina 2007.

5. Bustos LH, Rojas PG, Barroso VG. Diagnóstico de esterilidad conyugal. En: Ahued AJ (ed.): Ginecología y Obstetricia aplicadas. Ciudad de México, Manual Moderno, 2003: 777-787.

6. Hernández-Valencia M, Zárate A. Amenorrea y trastornos de la menstruación. Acta Médica Grupo Ángeles 2006; 3: 197-201.

7. Lovely LP, Fazleabas AT, Fritz MA, McAdams DG, Lessey BA. Prevention of endometrial apoptosis: randomized prospective comparison of human chorionic gonadotropin versus progesterone treatment in the luteal phase. J Clin Endocrinol Metab 2005; 90: 2351-2356.

8. Daya S, Gunby J. Apoyo de la fase lútea en los ciclos de reproducción asistida (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2006 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (Traducida de The Cochrane Library, 2006 Issue 4. Chichester, UK: John Wiley & Sons, Ltd.).

9. Rojas SJ. Aborto espontáneo. En: Ahued AJ (ed.): Ginecología y obstetricia aplicadas. Ciudad de México, Manual Moderno, 2003: 289-293.

10. Menocal TG, Sánchez UR, Hurtado AR y cols. Apego a la suplementación de fase lútea con progesterona oleosa inyectable en tratamiento reproductivo. Ginecología y Obste de Mex 2008; Supl: 8-13.

11. Fanchin R, Ziegler D, Bergeron C et al. Transvaginal administration of progesterone. Obstetrics & Gynecology 1997; 90: 396-401

12. Fuentes S, Redondo L. Técnica para aplicación de inyecciones. En: Manual fundamentos de enfermería cuidados básicos. Barcelona, Ariel Ciencias Médicas, 1984: 176-184.